Orthofix Investor Presentation Deck

Quarterly Highlights ● SECOND QUARTER 2022 $118 million in net sales, flat on a constant currency basis versus the prior year Global Orthopedics net sales growth of 11% on a constant currency basis driven by new products and channel expansion Executed partnership with CGBio to commercialize NovosisTM rhBMP-2 growth factor in the United States and Canada Limited launch of VirtuosTM Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute $121 M ● 63% Q2 21 $112 M 1% Q3 21 REVENUE $125 M 7% Q4 21 $106 M 2% Q1 22 $118 M 0% Q2 22 Percentages represent sales growth in constant currency vs. prior year Quarterly results are impacted by COVID and seasonality ORTHOFIX 19

View entire presentation